On October 9th, Geelong announced that Mengke Pharmaceuticals (688373.SH) plans to adjust the investment amount in MicuRx Pharmaceuticals, Inc. from $80 million to $60 million, with the contribution method still being cash investment. The company will, based on the funding situation, authorize management to implement the capital increase scheme in batches with its own or self-raised funds after completing the corresponding approval procedures.